- Home
- LUCY vs HSCS Comparison
LUCY vs HSCS Comparison
Compare LUCY & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- HSCS
- Stock Information
- Founded
- LUCY 2017
- HSCS 2007
- Country
- LUCY United States
- HSCS United States
- Employees
- LUCY N/A
- HSCS N/A
- Industry
- LUCY Ophthalmic Goods
- HSCS Medical Specialities
- Sector
- LUCY Health Care
- HSCS Health Care
- Exchange
- LUCY Nasdaq
- HSCS Nasdaq
- Market Cap
- LUCY 8.7M
- HSCS 8.7M
- IPO Year
- LUCY 2022
- HSCS 2022
- Fundamental
- Price
- LUCY $1.92
- HSCS $3.52
- Analyst Decision
- LUCY
- HSCS Strong Buy
- Analyst Count
- LUCY 0
- HSCS 2
- Target Price
- LUCY N/A
- HSCS $13.00
- AVG Volume (30 Days)
- LUCY 194.2K
- HSCS 86.8K
- Earning Date
- LUCY 11-11-2025
- HSCS 09-11-2025
- Dividend Yield
- LUCY N/A
- HSCS N/A
- EPS Growth
- LUCY N/A
- HSCS N/A
- EPS
- LUCY N/A
- HSCS N/A
- Revenue
- LUCY $1,978,018.00
- HSCS $6,250.00
- Revenue This Year
- LUCY $149.32
- HSCS $13,968.97
- Revenue Next Year
- LUCY $400.00
- HSCS $166.67
- P/E Ratio
- LUCY N/A
- HSCS N/A
- Revenue Growth
- LUCY 29.30
- HSCS N/A
- 52 Week Low
- LUCY $1.57
- HSCS $2.52
- 52 Week High
- LUCY $11.16
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- LUCY 47.74
- HSCS 52.54
- Support Level
- LUCY $1.82
- HSCS $3.00
- Resistance Level
- LUCY $1.98
- HSCS $3.70
- Average True Range (ATR)
- LUCY 0.10
- HSCS 0.21
- MACD
- LUCY 0.01
- HSCS 0.03
- Stochastic Oscillator
- LUCY 51.22
- HSCS 74.29
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.